Keyword Search 2019 | 2018 | 2017 | 2016 | 2015 | 2014DateTitle 09/26/16Aerpio Therapeutics Initiates Phase 1a Study of AKB-4924, a First in Class Once-Daily, Orally Administered HIF-1 Stabilizer, in Development to Treat Inflammatory Bowel Disease (IBD) ... 06/13/16Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial... 02/10/16Aerpio Therapeutics Announces Presentation of Positive Results of AKB-9778 in Patients with Diabetic Retinopathy from TIME-2 Phase 2a Study ... Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts
